ResMed Inc. 10-Q Summary: Quarter Ended September 30, 1999
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep disordered breathing, primarily obstructive sleep apnea. The reporting period covers the three months ended September 30, 1999. Principal manufacturing operations are located in Australia, with major distribution and sales sites in the United States, United Kingdom, Singapore, and Europe.
Key Financial Metrics
| Metric | Q1 1999 (3 Months) | Q1 1998 (3 Months) |
|---|---|---|
| Net Revenue | $25,945,000 | $19,244,000 |
| Gross Profit | $17,721,000 | $13,160,000 |
| Gross Margin | 68.3% | 68.4% |
| Operating Income | $7,422,000 | $5,372,000 |
| Net Income | $4,835,000 | $3,184,000 |
| Diluted EPS | $0.31 | $0.21 |
| Cash from Operations | $3,797,000 | $4,384,000 |
| Cash & Equivalents (End Period) | $10,835,000 | $16,476,000 |
| Working Capital | $35,910,000 | N/A |
Liquidity & Debt: The company reported no long-term debt in the provided balance sheet excerpts. Total current liabilities were $20,317,000. Cash and cash equivalents plus marketable securities totaled approximately $17.5 million as of September 30, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 35% ($6.7 million) driven by higher unit sales of flow generators and accessories in North/Latin America and Europe.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 32% due to an increase in sales and administrative personnel (from 169 to 227). R&D expenses increased 32% due to consulting fees and clinical trials for new products.
- Other Income: Other income (expense) improved significantly from a net expense of $541,000 in 1998 to net income of $5,000 in 1999, primarily due to lower foreign currency losses.
- Cash Flow: Net cash provided by operating activities decreased to $3.8 million from $4.4 million, offset by increased inventory holdings and accounts receivable.
Outlook, Risks, and Contingencies
- Guidance & Capital Needs: Management anticipates expending approximately $1.5 million over the next six months for Oracle Application Enterprise and eCommerce initiatives, funded by operating cash flows.
- Legal Proceedings: Ongoing patent litigation with Respironics in the U.S. (summary judgment motions granted to Respironics, ResMed intends to appeal) and an unfair trade practices claim in Australia seeking approximately $1 million in damages. No assurance of success is provided.
- Year 2000 Compliance: The company believes its systems and products are compliant. However, risks remain regarding third-party suppliers and infrastructure. Estimated total cost for Oracle implementation is $3 million.
- Foreign Exchange: Significant exposure to Australian Dollar and European currencies. The company uses foreign currency options to hedge risks, with notional amounts totaling $124.3 million as of September 30, 1999.
- Accounting Changes: SFAS No. 133 regarding derivative instruments becomes effective September 30, 2000; impact is currently undetermined.
Investor Verification Checklist
- Verify the status and potential financial impact of the patent litigation against Respironics, specifically the appeal of summary judgment rulings.
- Confirm the timeline and budget adherence for the Oracle Application Enterprise implementation ($3 million total estimate).
- Monitor foreign currency exchange rates, particularly the Australian Dollar, given the company's manufacturing base and hedging strategy.
- Assess the readiness of key third-party suppliers and infrastructure for Year 2000 compliance to mitigate disruption risks.
- Review future inventory levels to ensure they align with sales growth without negatively impacting cash flow.